BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CTI Mirada Solutions Awarded FDA 510(k) Clearance To Market Scenium(TM) For Analysis Of Neurological PET Scans


10/19/2005 5:12:24 PM

KNOXVILLE, Tenn., Jan. 18 /PRNewswire-FirstCall/ -- CTI Molecular Imaging, Inc. , a leading provider of positron emission tomography (PET) equipment, molecular biomarkers and services, today announced that its subsidiary CTI Mirada Solutions, has been awarded FDA 510(k) clearance to market Scenium, an innovative new quantification tool for the analysis of neurological positron emission tomography (PET) scans.

Scenium display and analysis software has been developed to aid clinicians in accurate assessment and quantification of dementia and other neurological diseases. Initially developed for use in PET studies with fluorodeoxyglucose (FDG), Scenium has the potential to be used with other PET molecular imaging agents in the future.

The software is organized as a series of workflows, each is specific to a particular radiopharmaceutical and disease combination. Based on Mirada's established image fusion techniques, Scenium enables clinicians to compare patients' brain scans to standard normal scans, highlighting differences in uptake. Multiple anatomical regions are highlighted for quick assessment of an image and quantitative comparison with other images and integration into the current reporting workflow of the imaging center.

The software will be available as a plug-in to a wide variety of viewing workstations, and also for use on a standard PC.

"Developed in direct response to the rapidly expanding market for quantification software, Scenium is expected to achieve a widespread install base during 2005, particularly with the recent approval for reimbursement for some neurological FDG scans," commented Christian P. Behrenbruch, president of CTI Mirada Solutions.

Mirada plans to release Scenium during spring 2005, following product optimization based on current field trials. The software will be distributed by CTI PETNET, as well as Mirada's OEM/PACS partners.

About CTI Mirada Solutions:

Mirada Solutions Limited, a wholly owned subsidiary of CTI Molecular Imaging, is a leading developer of software and analytical tools for medical imaging workstations, OEM imaging platforms and image analysis in pharmaceutical R&D. Mirada's unique products aid in better detection, diagnosis and management of disease through the application of powerful algorithms, quantification tools and image analysis. Additional information is available at http://www.mirada-solutions.com/

About CTI Molecular Imaging:

CTI Molecular Imaging, Inc. is a leading supplier of products and services for positron emission tomography (PET), a diagnostic imaging technology used in the detection and treatment of cancer, cardiac disease and neurological disorders. Additional information is available at: http://www.ctimi.com/

Certain matters discussed in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by words such as "believe," "assume," "expect," "anticipate," "intend," "estimate" or similar expressions, and any other statements that necessarily depend on future events. Forward-looking statements involve a number of risks and uncertainties and there can be no assurance that any forward-looking statements will prove to be accurate. Various factors could cause actual results to differ materially from those anticipated in the forward-looking statements. CTI undertakes no obligation to update or revise any forward-looking statements. Further information regarding risks, uncertainties and other factors that could adversely affect CTI or cause actual results to differ materially from those anticipated in forward-looking statements are included in CTI's Annual Report on Form 10-K for the fiscal year ended September 30, 2004.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding CTI Molecular Imaging, Inc.'s business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report or Form 10-K for the most recently ended fiscal year.

CTI Molecular Imaging, Inc.

CONTACT: Lisa Baird of CTI Molecular Imaging, Inc., +1-865-218-2507; orClare F. Jones of CTI Mirada Solutions, +44 1865 265500



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES